Citigroup Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $21.00

Arcturus Therapeutics (NASDAQ:ARCT) had its target price cut by Citigroup from $66.00 to $21.00 in a research report released on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Other equities analysts also recently issued reports about the stock. Roth Mkm began coverage on shares of Arcturus Therapeutics in a research note on Thursday, January 22nd. They set a “buy” rating and a $20.00 price objective for the company. Piper Sandler cut their target price on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday. Wall Street Zen lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright cut their price objective on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $30.33.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock opened at $7.11 on Thursday. Arcturus Therapeutics has a 52-week low of $5.85 and a 52-week high of $24.17. The company’s 50 day moving average price is $7.32 and its 200-day moving average price is $11.21. The stock has a market capitalization of $202.09 million, a price-to-earnings ratio of -2.99 and a beta of 2.40.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.11). The firm had revenue of $7.20 million for the quarter, compared to the consensus estimate of $14.32 million. Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. As a group, equities research analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARCT. ARK Investment Management LLC lifted its stake in shares of Arcturus Therapeutics by 9.2% in the 3rd quarter. ARK Investment Management LLC now owns 1,872,721 shares of the biotechnology company’s stock valued at $34,514,000 after purchasing an additional 157,681 shares during the period. Amova Asset Management Americas Inc. boosted its position in shares of Arcturus Therapeutics by 6.4% during the third quarter. Amova Asset Management Americas Inc. now owns 1,947,835 shares of the biotechnology company’s stock valued at $35,879,000 after purchasing an additional 117,632 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Arcturus Therapeutics by 6.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,947,835 shares of the biotechnology company’s stock worth $35,899,000 after purchasing an additional 115,368 shares during the period. Y Intercept Hong Kong Ltd raised its holdings in Arcturus Therapeutics by 92.5% in the second quarter. Y Intercept Hong Kong Ltd now owns 44,432 shares of the biotechnology company’s stock worth $578,000 after purchasing an additional 21,355 shares in the last quarter. Finally, Gateway Investment Advisers LLC bought a new position in Arcturus Therapeutics in the third quarter worth $737,000. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics News Summary

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Company will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 11), giving management a near‑term opportunity to provide program updates and financing/cost‑pathway clarity that could stabilize sentiment. Arcturus Therapeutics to Attend Upcoming Investor Conference
• Neutral Sentiment: Citigroup cut its price target from $66 to $21 but maintained a “buy” rating — this reduces a high upside anchor and likely tempers conviction among momentum buyers, though the maintained buy stance leaves room for positive reaction if management news is constructive. Citi price target cut coverage
• Neutral Sentiment: Short‑interest data published for early March appears to be erroneous (shows 0 shares / NaN changes); investors should treat those metrics with caution until corrected — unreliable short data reduces clarity on potential short‑squeeze dynamics. (Source: market data entries)
• Negative Sentiment: HC Wainwright materially lowered EPS forecasts across 2026–2030 (e.g., FY2026 cut to ($3.07) from ($2.19); FY2029 and FY2030 swung to large expected losses), and reduced quarterly EPS estimates for Q1–Q4 2026 — this increases downside pressure by signaling a longer path to profitability and higher cash burn assumptions. HC Wainwright estimate revisions (market summary)
• Negative Sentiment: Recent Q4 earnings commentary and third‑party assessments highlighted missed revenue and EPS vs. expectations, reinforcing short‑term weakness and investor skepticism until clinical/program milestones or clearer financing plans are provided. Arcturus Therapeutics Q4 2025 Earnings Call Summary Q4 earnings assessment

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.